IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $21,612,338 | -25.8% | 4,749,411 | +14.8% | 0.00% | 0.0% |
| Q2 2023 | $29,134,077 | +56.9% | 4,138,362 | +36.2% | 0.00% | +50.0% |
| Q1 2023 | $18,570,944 | +103463.1% | 3,039,433 | +8.3% | 0.00% | -33.3% |
| Q4 2022 | $17,932 | -99.9% | 2,806,381 | +5.0% | 0.00% | -25.0% |
| Q3 2022 | $25,599,000 | -12.2% | 2,672,158 | +1.2% | 0.00% | 0.0% |
| Q2 2022 | $29,144,000 | -7.8% | 2,639,889 | +39.1% | 0.00% | 0.0% |
| Q1 2022 | $31,604,000 | -10.4% | 1,898,187 | +2.7% | 0.00% | 0.0% |
| Q4 2021 | $35,274,000 | -19.9% | 1,847,811 | +3.5% | 0.00% | -33.3% |
| Q3 2021 | $44,043,000 | -7.5% | 1,786,012 | -2.4% | 0.01% | -14.3% |
| Q2 2021 | $47,596,000 | -12.7% | 1,829,236 | +6.2% | 0.01% | -12.5% |
| Q1 2021 | $54,544,000 | -29.2% | 1,722,823 | +3.8% | 0.01% | -38.5% |
| Q4 2020 | $77,017,000 | +49.5% | 1,659,861 | +6.1% | 0.01% | +30.0% |
| Q3 2020 | $51,519,000 | +17.2% | 1,564,985 | -2.3% | 0.01% | +11.1% |
| Q2 2020 | $43,950,000 | -17.2% | 1,601,146 | -9.7% | 0.01% | -35.7% |
| Q1 2020 | $53,055,000 | -42.2% | 1,772,369 | -46.5% | 0.01% | +40.0% |
| Q4 2019 | $91,734,000 | +219.1% | 3,314,116 | +109.8% | 0.01% | +42.9% |
| Q3 2019 | $28,744,000 | -28.2% | 1,579,401 | -3.3% | 0.01% | -30.0% |
| Q2 2019 | $40,030,000 | +185.7% | 1,632,556 | +10.8% | 0.01% | +150.0% |
| Q1 2019 | $14,012,000 | -41.1% | 1,473,408 | -45.2% | 0.00% | 0.0% |
| Q4 2018 | $23,800,000 | +140.8% | 2,689,404 | +206.1% | 0.00% | +33.3% |
| Q3 2018 | $9,882,000 | +1.6% | 878,484 | +15.5% | 0.00% | 0.0% |
| Q2 2018 | $9,731,000 | -12.3% | 760,308 | +15.8% | 0.00% | -25.0% |
| Q1 2018 | $11,098,000 | +141.7% | 656,714 | +14.4% | 0.00% | +100.0% |
| Q4 2017 | $4,592,000 | +12.9% | 574,043 | +9.4% | 0.00% | 0.0% |
| Q3 2017 | $4,067,000 | +6.9% | 524,892 | +1.4% | 0.00% | +100.0% |
| Q2 2017 | $3,804,000 | – | 517,648 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |